Guideline / position statementindependent cross-checkabstract only checked I-SUP-05 standard review

Endocrine Society 2024 vitamin D guideline

Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.

Overview

Demay MB et al.. J Clin Endocrinol Metab 2024 · PMID 38828931 · DOI 10.1210/clinem/dgae290

Suggests vitamin D for children, pregnancy, people ≥75 and high-risk prediabetes.

Does the study support the specific claim? No · Methodological quality: high

Original publication

Plain-language summary

Study explained simply
What did the researchers want to find out?

Vitamin D for prevention.

How was the study done?

Guideline.

What was actually found?

Group-specific suggestions.

What do the results mean in everyday life?

Some groups benefit.

What are the study's limitations?

Conditional.

What does it say about Elawady's specific claim?

Contradicts blanket ban.

Do the results apply to Germany and Europe?

Applicable.

What can explicitly not be concluded from this study?

Doses.

Scientific in-depth review

1. Full reference

Authors
Demay MB et al.
Journal
J Clin Endocrinol Metab
Year
2024
Identifier
PMID 38828931 DOI 10.1210/clinem/dgae290
Verification
verified – PubMed efetch 2026-10-25
Retracted
no
Corrections

ErratumIn: J Clin Endocrinol Metab. 2025 Feb 18;110(3):e916. doi: 10.1210/clinem/dgae854.; ErratumIn: J Clin Endocrinol Metab. 2025 Jul 15;110(8):e2810. doi: 10.1210/clinem/dgaf310.

Extent checked
abstract only
Conflicts of interest and funding

not stated in abstract

2. Research question

Vitamin D for prevention of disease in people without established indications

3. Study design and population

Study design
Guideline / position statement – Clinical practice guideline (Endocrine Society), GRADE
Population

General population by age group, pregnancy, prediabetes

Country

International

Period

2024

Inclusion and exclusion criteria

No established indication for vitamin D or 25(OH)D testing

4. Methods and endpoints

Exposure / intervention

Empiric vitamin D

Comparator

No empiric supplementation

Endpoints

Various

Statistical methods

GRADE

5. Actual results

Results

Suggests empiric vitamin D for ages 1–18 (rickets prevention, possible respiratory infection reduction), ≥75 years (possible mortality reduction), pregnancy (possible lower preeclampsia, intrauterine mortality, preterm, SGA, neonatal mortality), high-risk prediabetes; daily rather than intermittent high doses for >50 years; against empiric supplementation above DRI for healthy adults <75.

Absolute risks

not applicable

Authors' conclusion

Empiric supplementation suggested for specific groups; optimal doses unclear.

6. Strengths

  • GRADE
  • Multidisciplinary

7. Weaknesses

  • Conditional recommendations
  • Errata

8. Risk of bias

Orienting tool
none applicable
Type of assessment
simplified assessment (abstract only)
Full formal assessment
no
Overall risk of bias
not assessable
Rationale

Guideline.

9. Assessment of the statistical interpretation

10. Relevance to the specific claim

C-SUP-07; C-SUP-10.

11. Independent contrary findings

12. Transferability to Germany and Europe

High.

13. Overall methodological judgement

Specific groups benefit; mega-doses discouraged.

Multidimensional assessment
Multidimensional assessment
Authenticity of the sourceverified
Methodological qualityhigh
Risk of biasnot assessable
Precision of resultsnot applicable
Directnessdirect
Reproducibilityunknown
Consistency with the overall evidenceconsistent
Regional transferabilityhigh
Adequacy of the interpretation (by the archive)not applicable

14. Open questions

Optimal dose.

15. Linked fact checks